Skip to content
sellWeak

David Hollander sold $16k of RVNC

CMO & Global Therapeutics Lead at Revance Therapeutics, Inc.. 3,908 shares at an average of $4.17, traded Nov 18, 2024, filed Nov 19, 2024.

Warning score
15
Value
$16k
3,908 shares
Holdings after
104,945
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $16k at market
    0
  • Share of holdings sold
    Sold 3.6% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001479290-24-000130, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 18, 2024SOpen-market sale
Common Stock
-3,908$4.17$16k104,945Nov 19, 2024

Related signals

Other insiders at Revance Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
RVNCsell
Revance Therapeutics, Inc.
Erica Jordan
Chief Commercial Officer
$9,096
2,392 shares
-2%
36Weak
RVNCsell 3
Revance Therapeutics, Inc.
Dwight Moxie
CLO & GC
$41k
8,125 shares
-6%
43Moderate
RVNCsell 3
Revance Therapeutics, Inc.
Tobin Schilke
CFO
$47k
9,361 shares
-5%
41Moderate
RVNCsell 3
Revance Therapeutics, Inc.
Dustin S Sjuts
President
$46k
9,211 shares
-5%
37Weak
RVNCbuy
Revance Therapeutics, Inc.
Mark J Foley
CEO
$209k
30,000 shares
+3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David Hollander sold $16k of RVNC | InsiderTell